gc012f
gracell
['multiple myeloma', 'gc012f ', 'gracell']
at the ongoing 2023, gracell biotechnologies shared extended follow-up data from a multicenter study that assessed the effectiveness of gc012f in patients with relapsed/refractory multiple myeloma (rrmm). click here to know more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry